Anti-thyroid peroxidase antibodies are associated with the absence of distant metastases in patients with newly diagnosed breast cancer

Farahati, Jamshid; Roggenbuck, Dirk; Gilman, Elena; Schütte, Martin; Jagminaite, Elena; Zakavi, Seyed Rasoul; Löning, Thomas; Heissen, E

doi:10.1515/cclm.2011.819

Cited by 26 publications

(24 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The data also suggested that lymph node involvement and hormone receptor-negative tumors (e.g., ER-negative) were also less frequent among hypothyroid patients, but this association was not statistically significant. In agreement with our study, Farahati et al (25) recently reported that the presence of TPOab is associated with a lower frequency of metastasis in breast cancer patients. However, in addition to that study, we observed that TPOab positivity may protect breast cancer patients from local recurrence or distant metastasis during the follow-up period.…”

Section: Discussionsupporting

confidence: 94%

Antithyroid peroxidase antibody positivity is associated with lower incidence of metastasis in breast cancer

Kemal

Demirağ

Ekiz

et al. 2015

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. Thyroid extracts were first used to treat patients with metastatic breast cancer over a century ago. Since then, a number of studies have investigated the association between thyroid disorders and breast cancer. The presence of antibodies to thyroid peroxidase (TPOab) was recently reported to be associated with improved outcome in these patients. The aim of the present study was to evaluate the association between TPOab positivity and clinicopathological characteristics in breast cancer patients. The study included 318 newly diagnosed cases of breast cancer treated at Ondokuz Mayis University Hospital, Samsun, Turkey, between 2008 and 2012. Serum thyroid-stimulating hormone, free triiodothyronine and free thyroxine levels were measured at the time of diagnosis. Of the 318 patients, 253 were considered to be TPOab-negative (TPOab ≤34 IU/ml) and 65 TPOab-positive (TPOab >34 IU/ml). No cases with distant metastases were found in the TPOab-positive group. However, 20 (7.9%) of the 253 patients displayed distant metastases in the TPOab-negative group (P=0.01). Therefore, TPOab positivity was found to be associated with a lower incidence of metastasis in breast cancer patients.

show abstract

Section: Discussionsupporting

confidence: 94%

Antithyroid peroxidase antibody positivity is associated with lower incidence of metastasis in breast cancer

Kemal

Demirağ

Ekiz

et al. 2015

Molecular and Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…18,22 Many studies showed the non-significant differences between the breast cancer patients and the control group in mean serum FT3 levels. 23,24,25 The serum free thyroxine (FT4) was significantly lower in the breast cancer patients when compared to the controls (p<0.05). There was no significant difference found between the pre-treatment CA breast, the fibrocystic disease patients and the controls (p>0.05).…”

Section: Discussionmentioning

confidence: 99%

Serum Thyroid Hormone Profile in Breast Cancer Patients

Jarari¹,

H²,

Peela³

et al. 2018

jemds

View full text Add to dashboard Cite

BACKGROUND Recent studies indicate a possible relationship between thyroid diseases and breast cancer in vivo. In addition, oestrogen-like effects of thyroid hormones on breast cancer cell growth are seen in vitro. Therefore, this prospective observational study evaluated thyroid function in breast cancer patients, women with the fibrocystic disease and healthy controls. MATERIALS AND METHODSThis was a prospective observational study. Pre-treatment group consisted of breast cancer patients who at the initial time of diagnosis (n= 28), post-treatment group comprising of patients who had undergone either chemotherapy/ radiotherapy or hormone therapy for their disease (n= 37). The fibrocystic group comprising of patients with benign breast tumour (n= 21) and 51 healthy control group consisted of members of the public with no prior history of breast cancer or other cancer-related disorders (n= 51) were included in the study. Thyroid history was reported. Thyroid hormones (FT4, FT3, TSH, T3, T4) and thyroid antibodies (TPO. Ab and TG. Ab) were determined. The Kruskal-Wallis H and Mann-Whitney U tests (p < 0.005 significant) were used for statistical analysis. RESULTSFree thyroxine measurements showed significant difference comparing both CA breast patients, pre-treatment (p= 0.009) and post-treatment (p= 0.001), respectively to the control group. There was no significant difference in free thyroxine levels between fibrocystic patients and control groups (p= 0.917) as well as a non-significant difference in free thyroxine levels was found between fibrocystic patients and post-treatment CA breast patients (p= 0.079). There was no significant difference in thyroxine (T4) measurement between breast cancer groups, fibrocystic group and normal healthy control group (p > 0.05). The free triiodothyronine (T3) measurements showed no significant difference between breast cancer groups, fibrocystic group and normal healthy control group (p > 0.05). The thyrotropin (TSH) measurements showed significant difference comparing both CA breast patients, pre-treatment (p= 0.016) and post-treatment (p= 0.01) respectively to the control group. The thyroid peroxidase antibodies (anti-TPO) measurements showed no significant difference between breast cancer groups, fibrocystic group and normal healthy control group (p > 0.05). CONCLUSIONThe subclinical hypothyroidism was seen more frequently in breast cancer patients, changing levels of thyroid hormones suggested dysregulation in breast cancer patients. These data must be confirmed in large patient's prospective observational study. Financial or Other Competing Interest': None. Submission 13-01-2018, Peer Review 25-01-2018, Acceptance 27-01-2018, Published 05-02-2018. Corresponding Author: Dr. Jagannadha Rao Peela, Department of Biochemistry and Medical Genetics, School of Medicine, St. Matthew's University, Leeward 3, Regatta Office Park, Grand Cayman, Cayman Islands-KY1-1204. E-mail: pjrao@stmatthews.edu DOI: 10.14260/jemds/2018 The World Health Organization (WHO) clas...

show abstract

“…That study differed from the current study in that they used qualitative data to determine thyroid disease, and they showed functional sensitivities for TgAb (positivity﹥60 U/ml) and TPOAb (positivity﹥60 U/ml). However, uniform positive criteria for TPOAb and TgAb have not been reported to date (Ditsch et al, 2010;Farahati et al, 2012;Szychta et al, 2013). A meta-analysis conducted in 2012 showed a confirmed relationship between AITD and BC by pooling the results of studies based on positive criteria for TPOAb and TgAb.…”

Section: Discussionmentioning

confidence: 99%

Relationship between Breast Cancer and Levels of Serum Thyroid Hormones and Antibodies: a Meta-analysis

Shi

Jin²,

Xu³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

The breast and the thyroid are hormone responsive organs that are closely related with changes of endocrine function and glandular disease. An association between thyroid disorders and breast cancer (BC) risk has been suggested, although the results are inconclusive. The purpose of the present study was to summarize evidence supporting a relationship between BC and the level of thyroid hormones and antibodies. The MEDLINE and EMBASE electronic databases were searched for studies published between 2000 and 2014. The pooled effects were presented as weighted mean differences (WMD) with 95% confidence intervals (CI) using fixed or random effect models. We summarized the results of 8 cross-sectional studies with 4, 189 participants. The overall pooled results showed that the levels of FT 3 and FT 4 were significantly increased in patients with BC (WMD=1.592 pmol/l; 95% CI: 0.15-3.033 and WMD=0.461 ng/dl; 95% CI: 0.015-0.906; p=0.043). The TPOAb level in patients with BC was higher than that in the control group (WMD=81.4 IU/ml; 95% CI: 78.7-84.0; p=0.000). The overall pooled results of the TgAb with random effects analyses showed that the TgAb level was significantly increased in patients with BC (WMD=101.3 IU/ml; 95% CI: 48.7-153.9; p=0.000). The present results indicated that the serum levels of FT 3 , TPOAb and TgAb are significantly higher in patients with breast cancer than in healthy controls.

show abstract

Anti-thyroid peroxidase antibodies are associated with the absence of distant metastases in patients with newly diagnosed breast cancer

Abstract: TPOab occurrence is associated with significantly lower frequency of distant metastases in breast cancer. TPOab level inversely correlates with the conventional tumor markers CA-15-3 and CEA.

Cited by 26 publications

References 35 publications

Antithyroid peroxidase antibody positivity is associated with lower incidence of metastasis in breast cancer

Antithyroid peroxidase antibody positivity is associated with lower incidence of metastasis in breast cancer

Serum Thyroid Hormone Profile in Breast Cancer Patients

Relationship between Breast Cancer and Levels of Serum Thyroid Hormones and Antibodies: a Meta-analysis

Contact Info

Product

Resources

About